FDA Authorizes First AI-ECG Model for STEMI Detection: What Queen of Hearts Could Change in the Cath Lab
The takeaway: The FDA has granted De Novo authorization to the first AI-ECG model built to flag STEMI and STEMI equivalents and to route the alert to the team that needs to act, and the early data suggest fewer false-positive cath lab activations.
Background
Every one of us has stared at an ECG at 2 a.m. wondering whether it is a true STEMI, a mimic, or an occlusion MI hiding behind subtle changes such as hyperacute T waves or a posterior MI. Missed or delayed recognition costs myocardium, while unnecessary cath lab activations cost teams, resources, and patient risk. Non-PCI hospitals feel this most, since expert over-read is not always available. That is the gap AI-ECG is trying to close.
What happened
As TCTMD reported, the Queen of Hearts model, deployed through the PMcardio platform, received De Novo authorization for detecting STEMI and STEMI equivalents in patients with suspected acute coronary syndrome. According to the manufacturer, Powerful Medical, the intended use goes beyond detection to include triage, prioritization, and notification of the appropriate cardiology team.
Key findings
- Regulatory path: The model received FDA breakthrough device designation in March 2025 and was enrolled in the FDA's Total Product Life Cycle Advisory Program (TAP). It has carried a CE Mark in Europe since 2022.
- US network data: Dr. Timothy Henry presented a retrospective registry study at TCT 2025, published in JACC: Cardiovascular Interventions, across three US primary PCI networks. The model outperformed standard decision-making for STEMI detection.
- Explainability: The platform shows why an ECG was called positive, which Henry noted could sharpen ECG recognition among clinicians.
| Retrospective registry (3 US PCI networks) | False-positive cath lab activation rate |
|---|---|
| With AI-ECG | 7.9% |
| Without AI-ECG (standard decision-making) | 41.8% |
Caveats worth keeping in mind
- The headline comparison comes from a retrospective registry, not a randomized or prospective trial. I would want prospective data on door-to-balloon time and hard outcomes before calling this practice-changing.
- The manufacturer says more than 20 peer-reviewed studies involving over 40,000 patients support the model. That is a company-reported summary, and I have not independently reviewed each study.
- Dr. Henry, who is quoted as predicting this will become standard of care, reports research support from Powerful Medical.
- The claim that no other authorized AI-ECG carries this indication also comes from the company.
Clinical takeaway
For those of us on the receiving end of STEMI calls, the appeal is practical: a second set of eyes at the moment of first ECG, especially at non-PCI centers, plus a possible reduction in activations that end with a clean angiogram. Henry expects uptake to accelerate, and the company says several US health systems are integrated and waiting to go live. My view is that this belongs as decision support alongside, not instead of, physician over-read. Watch for prospective and implementation data, including how alerts perform in your own ED workflow.
References
- Neale T. FDA Clears First AI-ECG Model for Acute MI Detection. TCTMD. September 9, 2026.
- Neale T. AI-ECG Finds STEMI Faster, Cuts False-Positive Cath Lab Activations. TCTMD. October 31, 2025.
- Henry T, et al. JACC: Cardiovascular Interventions. 2025 (DOI: 10.1016/j.jcin.2025.10.018).
- Powerful Medical. FDA Breakthrough Device Designation for PMcardio STEMI AI-ECG Model.
- US FDA. Total Product Life Cycle Advisory Program (TAP).
